GE HealthCare Technologies Inc. is gaining traction in the market, thanks to recent advancements in its product offerings.
GE HealthCare (NASDAQ:GEHC) is up today, with shares rising 3.18% to close at CA$70.65. The company is seeing positive movement after announcing significant advancements in its product lines and participating in key research initiatives.
Advertisement
GE HealthCare Technologies Inc.
GEHC.US
GEHC.US
GE HealthCare Technologies Inc.
WealthAwesomeMarket cap
$31.15B
P/E
15.7x
Div. yield
0.20%
Div. / share
$0.14
52W high
$89.64
52W low
$58.72
1W change
+5.88%
Beta
0.85
Analyst Price Targets
Based on 21 analysts covering GEHC · as of Oct 14, 2026
Wall Street analysts forecast GEHC stock price to rise 20.8% over the next 12 months.
Consensus
Buy4.24 / 5.00
Avg. Target
C$82.70
+20.8% Upside
Previously C$82.90 on Oct 12, 2026
Current Price
C$68.47
Last close
Analyst Breakdown (21 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on GEHC's historical volatility
30-Day Vol
23.4%
Annualized
90-Day Vol
35.0%
Annualized
Trend (90d)
+41.7%
Annualized drift
90d Mean
C$79.45
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$71.95 | C$66.37 – C$78.01 |
| 60 trading days | C$75.61 | C$67.44 – C$84.76 |
| 90 trading days | C$79.45 | C$69.07 – C$91.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors may find GE HealthCare's recent developments, especially in molecular imaging and groundbreaking research participation, promising for future growth.
3.18% Increase in Share Price
This increase reflects positive investor sentiment following recent product advancements and strategic partnerships.
Bull case
The recent CE Mark approval for the MINItrace Magni cyclotron and the expansion of the PETtrace Solid Target Platform to include Copper-64 positions GE HealthCare as a leader in molecular imaging. This could drive future revenue growth.
Bear case
Despite today's gains, there are concerns about the company's slow organic growth and shrinking operating margins, which could hinder long-term performance.
Recent Product Advancements
Advertisement
GE HealthCare's MINItrace Magni has achieved CE Mark approval, allowing healthcare providers to produce essential radioisotopes for PET imaging locally. This compact, automated cyclotron is designed to enhance molecular imaging programs, meeting the growing demand for reliable access to PET tracers.
Participation in Key Research Initiatives
The company has joined the EXIT-CVD research consortium, which aims to innovate cardiovascular disease detection and treatment. This collaboration with leading healthcare institutions highlights GE HealthCare's commitment to advancing healthcare technology and improving patient outcomes.
Market Outlook and Investor Sentiment
While today's rise is encouraging, investors should remain cautious. The company's recent performance has raised concerns about its organic growth and profitability. Analysts suggest monitoring GE HealthCare's ability to leverage its recent advancements for sustained growth in a competitive market.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
